Monthly Archives: August 2021

Diabetes startup brews up $11M after ‘serendipitous spill’ led to creation of new CGM tech – FierceBiotech

Posted: August 18, 2021 at 2:14 am

Many of the most groundbreaking discoveries have happened accidentally: The microwave oven, for one, was developed after physicist Percy Spencer noticed a chocolate bar in his pocket had melted while he was experimenting with a magnetron. Penicillin was born out of the bacteria-killing mold that grew on a petri dish while biologist Alexander Fleming was on vacation.

Perhaps aiming to join their ranks is Israeli startup Hagar, with itsGWave technology that measures blood sugar levels using noninvasive radio waves rather than an implanted sensor or repeated fingersticks.

According to Hagar lore, the technology came about after Geri Waintraub, the companys co-founder and chief technology officer, accidentally spilled a cup of tea on a radio frequency device during a separate research project and concluded that the ensuing reaction was caused by the sugar in his tea. Thus, GWave was born.

RELATED: Dexcom gets FDA go-ahead to pair diabetes data with Garmin, Livongo and more through 3rd-party APIs

The first generation of the GWave sensor is a device about a third the size of a standard smartphone,inserted into a ceramic bracelet. It uses Bluetooth to transmit its glucose readings to an accompanyingmobile app that tracks readings and alerts users to fluctuations in their blood sugar levels.

While radio waves are a form of electromagnetic radiation,GWave produces significantly less amounts than a smartphone, according to Hagar.

A proof-of-concept study found the company's radio frequency technology was able to continuously measure glucose levels with at least 90% accuracy, compared to the estimated 70% rate for traditional continuous glucose monitors.

According to the company, that difference stems from the fact that Hagars system directly measures glucose in the blood in real time. Other CGMs may use a sensor implanted under the skin to take measurements from the interstitial fluid between cells and may often have to be calibrated throughout the day with routine fingerstick blood tests.

RELATED: One Drop poaches Sanofi's head of diabetes innovation to bring CGM biosensor to market

Backed by those promising results, and with Hagar now planning to launch clinical trials to pursue FDA approval of the GWave system, the company has raised $11.7 million in series B funding.

The financing was led by Columbia Pacific and comes shortly after Hagar closed its series A, which brought in$4.4 million just last March. Those back-to-back funding rounds bring the companys lifetime funding to just over $17 million.

With 8.3% of the U.S. population living with diabetes today, that number is projected to rise to one in three adults by 2050. Finding a way to monitor glucose levels in the bloodcontinuously, painlessly and easilyis life-changing for those living with diabetes, and we are thrilled that our partners at Columbia Pacific are helping us in this journey, said CEO Guy Zur.

Next up, along with plotting out clinical trials of its technology, Hagar will continue developing the second-generation GWave device. In that iteration, the sensor will be embedded into a smartwatch that will be able to display the readings collected by the GWave mobile app.

Read the original:
Diabetes startup brews up $11M after 'serendipitous spill' led to creation of new CGM tech - FierceBiotech

Posted in Diabetes | Comments Off

Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing – Yahoo Finance

Posted: August 18, 2021 at 2:14 am

GBS Inc. is presenting at the Benzinga Healthcare Small Cap Conference on September 29, 2021.

For some people with diabetes, testing with a pinprick is no more than a minor inconvenience. But for many adults with testing phobias, they not only face the possibility of a rapid heartbeat or even passing out but could also skip much-needed glucose testing, putting their lives at risk.

GBS Inc. (NASDAQ: GBS) understands that testing anxiety can be a life-or-death dilemma and is on a mission to develop non-invasive, real-time diagnostic testing in the hands of patients and their primary health practitioners at the point-of-care.

Point of care testing company, GBS, has developed the first saliva-based Biosensor Platform and is launching diagnostic tests to help change the lives of people with diabetes and help combat COVID-19 and its variants with a real-time antibody test to monitor infection and immunity levels.

The Companys most advanced product is the Saliva Glucose Biosensor. It uses an organic thin-film transistor, incorporating glucose oxidase as the recognition element to initiate an electrochemical reaction, producing a signal that displays glucose measurements in real-time on an app or dedicated device.

Diabetes is a global chronic health issue with more than 400 million people in the world living with this disease, and that figure is expected to increase to 700 million by 2045, GBS Chief Executive Officer Harry Simeonidis stated. People living with diabetes need to feel confident and comfortable using a glucose monitoring device to help manage and supplement their medication administration.

GBS has also conducted its own global survey of diabetes patients to verify the need for its Saliva Glucose Biosensor. In all target markets, 90% of patients responded positively to the Biosensor Platform, with 7 out of 10 patients seriously interested in purchasing the product when released, and 3 out of 10 wanting placement on the waiting list ahead of release.An interesting sidelight to the survey found that while patients in the United States indicated the price of a pain-free alternative to current glucose monitoring would play a role in determining their decision to upgrade to a new device, patients in China indicated price was not an issue, as long as the product was accurate and reliable. The global survey included more than 300 patients worldwide living with diabetes.

Story continues

COVID-19 Developments

Intending to gain U.S. Food and Drug Administration review, GBS has begun research protocols with The Wyss Institute for Biologically Inspired Engineering at Harvard University to progress with the milestone of integrating its technology with the Companys Biosensor for SARS-Cov-2 antibody tests.

GBS has also initiated a study for the salivary collection protocol with Johns Hopkins University, Bloomberg School of Public Health and has completed technical optimization of Wysss eRapid assay performance in relation to SARS-Cov-2 antibody detection at the institute to align with the fastest antibody tests currently on the market using clinical samples.

Australian Government Awards Grant

GBS has been awarded a $4.7 million (USD) grant from the Australian federal government. The funding will be used to build a biosensor manufacturing facility and was chosen as 1 of 6 national manufacturing priorities identified by the government under its Modern Manufacturing Strategy.

The Australian interest ties back to the roots of GBSs technology, which results from 20 years of research and development by the countrys University of Newcastle Centre for Organic Electronics.

For more information on GBS Inc., go to http://www.gbs.inc.

Photo courtesy of GBS Inc.

See more from Benzinga

Posted in Diabetes | Comments Off

Welwitschia: genetics unveil the secrets of the immortal plant – EL PAS in English

Posted: August 18, 2021 at 2:10 am

When Joseph Dalton Hooker, director of the Kew Royal Botanical Gardens in London between 1865 and 1885, first cast his gaze on an example of Welwitschia he could not contain himself: It is without question the most wonderful plant ever brought to this country, and one of the ugliest. This species, Welwitschia mirabilis, was first formally described in 1863 and has been the subject of debate ever since it was first discovered. It has been established that it can survive for thousands of years in the harshest environments, making it the longest-living plant on the planet. But a recent genetic analysis published in Nature Communications has revealed new data about this curious plant species. Welwitschias duplicated genome means that some of its genes can dedicate themselves to tasks that are not part of their original functions. Furthermore, this species can activate certain proteins to protect itself from the extreme conditions in which it lives and it grows slowly but continuously throughout its entire life.

Welwitschia is found in Namibias northwest and southeastern Angola, an area dominated by the Kaokoveld Desert. Despite being geographically near to the coast, this region is arid and annual rainfall is less than five cubic centimeters. The plants appearance is also distinctive, consisting of two foliage leaves that can grow by 10 to 13 centimeters each year. As they grow, the tips of the leaves dry out and curl together, which sometimes lends the plant an appearance similar to an octopus.

Genome analysis of Welwitschia has shown that all of its genes are duplicated, what experts describe as genetic redundancy. Andrew Leitch, a researcher at the Queen Mary University of London and one of the authors of the study, explains how this duplicity, over the course of millions of years, has altered the functioning of these genes: The duplicated copies can take on new functions and do new things that would be impossible if there was only one version of the gene. These adaptations have driven the evolution of the plants. For example, the researchers believe that the leaves are capable of absorbing some of the humidity from clouds of mist that form in the plants natural habitat when dawn breaks.

Welwitschias genetic duplication began around 86 million years ago and was prompted by the stress placed on the plants by being constantly exposed to some of the harshest environmental conditions on the planet (high temperatures, ultraviolet radiation, salinity and so forth). In the face of this constant assault, Welwitschia always maintains a variety of proteins overactivated that allow the plant to keep these environmental stress factors at bay. Leitch explains it with a culinary example: When you put an egg in boiling water, the proteins in the egg are denatured and the white of the egg hardens. This denaturalization is a problem for the plants and animals that live in conditions of extreme heat and Welwitschia activates certain genes to prevent this from happening.

Identifying genes that allow for survival in hostile conditions will be useful when we are looking to grow crops in ever more marginal areas of the planet

Furthermore, unlike other plants, Welwitschias growth does not occur at the tips of the leaves but at the base. This area of the plant is heavily protected by two lips consisting of a woody fiber that cover the basal meristem, the part of the plant that supplies new cells. This type of bulb is formed of a practically embryonic tissue, still poorly defined, that gradually transforms into leaf tissue at a very slow pace. While this bulb lives, the plant will never stop growing. As such, the name given to it in Afrikaans is tweeblaarkanniedood, which literally translates astwo leaves that cannot die. The plants can live to such an age that the researchers had to use carbon-dating technology usually reserved for fossils to determine how old their subjects were. The results confirmed that some individuals were more than 1,500 years old.

Leitch believes that this discovery could prove to be key in the medium- to long-term for the survival of the human race. Identifying genes that allow for survival in hostile conditions will be useful when we are looking to grow crops in ever more marginal areas of the planet, something that we will have to do to be able to feed the nine billion people that we will be within the next 50 years with a high-level diet, as well as finding space for bio-combustibles. And all of that has to be achieved in a context of climate change and alterations in rainfall and temperature.

Alfonso Blzquez, a professor and researcher at the Autonomous University of Madrid who did not take part in the study, harbors doubt over the viability of this potential application. Overexpressing one or two genes in commercial crops is unlikely to achieve the same effect, because this plant has a battery of protective genes activated at the same time, but they may obtain some kind of greater resistance to heat or a lack of humidity. This could be an intermediate application that should be investigated.

English version by Rob Train.

Posted in Genetics | Comments Off

Join us today for Extra Crunch Live, as we speak with 1910 Genetics Jen Nwankwo and Playground Globals Jory Bell – TechCrunch

Posted: August 18, 2021 at 2:10 am

Our Extra Crunch Live series continues with some heavy hitters in August, including Jen Nwankwo, founder and CEO at 1910 Genetics, and Playground Global general partner Jory Bell. Theyll be with us live on August 11 at 12 p.m. PT (3 p.m. ET) to tell us all about how Nwankwo and her startup won over Bell and Playground as an investor, and as we do every week on Extra Crunch Live, well conduct a live pitch feedback session featuring you, the members of our audience.

Extra Crunch Live gives you the chance to hear live from entrepreneurs who have successfully raised significant rounds of venture capital and from the investors who believed in them. We go into detail about how the deal got done, and youll hear from both about what it takes to pitch VCs and what industry-leading VCs look for in prospective portfolio companies.

Were thrilled to have Nwankwo and Bell joining us for this episode. Nwankwo founded and leads 1910 Genetics, which takes advantage of AI to accelerate the discovery and development of new drug therapies across a wide range of disease and condition categories. She has a Ph.D. in pharmacology and experimental therapeutics from Tufts University School of Medicine and participated in drug discovery development that led to the creation of Type 2 diabetes drug Trulicity prior to her graduate school work.

Bells career includes designing and building autonomous robots for deep-sea exploration, as well as a six-year stint at Apple designing notebooks for the consumer technology leader. Bells venture investment work began at Playground Global in 2015; he focuses on deep tech investments, including in aerospace, genomics, synthetic biology, and AI-assisted drug discovery, as in the case of 1910 Genetics.

Extra Crunch Live also features the ECL Pitch-off, where startups in the audience can virtually raise their hand to pitch their startup live on our stream. Our expert guests will give their feedback on each pitch. If you want to throw your hat in the ring, you have to show up.

Extra Crunch Live is accessible to everyone, but only Extra Crunch members can access the content on demand. We do these every week, so there are scores of episodes across a wide variety of startup sectors in the ECL Library. Its but one of many reasons to become an Extra Crunch member. Join here.

Interested in hanging with us for this upcoming episode? Register here for free!

See original here:
Join us today for Extra Crunch Live, as we speak with 1910 Genetics Jen Nwankwo and Playground Globals Jory Bell - TechCrunch

Posted in Genetics | Comments Off

Lifeline Hospital offers solution for genetic diseases with advanced tech – The New Indian Express

Posted: August 18, 2021 at 2:10 am

By Express News Service

KOCHI:Rare genetic diseases can shatter families, as demonstrated recently by the crowdfunding appeals to meet the exorbitant cost of medicine for the treatment of children affected by spinal muscular atrophy (SMA). According to doctors, with improved medical technology, genetic disorders can be treated. Lifeline Hospital, Adoor, offers In Vitro Fertilisation with Pre-Implantation Genetic Diagnosis (PGD).

The birth of an affected child can be prevented by prenatal diagnosis and PGD. Prenatal diagnosis is possible by Chorionic Villus Sampling/Amniocentesis followed by continuation/termination of pregnancy. Preimplantation genetic diagnosis is a clinically feasible technology to prevent the transmission of monogenic inherited disorders in families afflicted by the diseases to the future offspring, said Dr Mathews John, medical director and general and laparoscopic surgeon at the hospital.

Individuals who are blood relatives are more likely to be silent carriers for the same recessive conditions, hence the risk of autosomal recessive genetic disorders is higher in children born from consanguineous parents, Dr Sreelatha Nair, consultant Geneticist and Head, Department of Genetics at the hospital.

The genetic department of the Lifeline Hospital, Advance Fertility and Gynaecology Centre, is one of the very few centres in India to provide Pre-Implantation Genetic Screening to needed couples. PGD would provide new reproductive options for families at risk for SMA and other similarly inherited autosomal recessive disorders, Dr Cyriac Pappachan, director and infertility specialist and laparoscopic surgeon, Lifeline Hospital.

Follow this link:
Lifeline Hospital offers solution for genetic diseases with advanced tech - The New Indian Express

Posted in Genetics | Comments Off

Global Regenerative Medicine Market Research Report 2021: Market to Surpass $50 Billion by 2027 – Cell Therapy Segment to Account for Half the Market…

Posted: August 18, 2021 at 2:09 am

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Global Regenerative Medicine Market to Reach $50.2 Billion by 2027

Amid the COVID-19 crisis, the global market for Regenerative Medicine estimated at US$12.2 Billion in the year 2020, is projected to reach a revised size of US$50.2 Billion by 2027, growing at a CAGR of 22.3% over the analysis period 2020-2027.

Cell Therapy, one of the segments analyzed in the report, is projected to record a 23.3% CAGR and reach US$25.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gene Therapy segment is readjusted to a revised 21.9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $3.7 Billion, While China is Forecast to Grow at 21.8% CAGR

The Regenerative Medicine market in the U.S. is estimated at US$3.7 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$8.7 Billion by the year 2027 trailing a CAGR of 21.8% over the analysis period 2020 to 2027.

Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 20.1% and 18.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 15.6% CAGR.

Tissue Engineering Segment to Record 21.1% CAGR

In the global Tissue Engineering segment, USA, Canada, Japan, China and Europe will drive the 21% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.7 Billion in the year 2020 will reach a projected size of US$6.3 Billion by the close of the analysis period.

China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$5.9 Billion by the year 2027.

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

For more information about this report visit https://www.researchandmarkets.com/r/6695iy

View original post here:
Global Regenerative Medicine Market Research Report 2021: Market to Surpass $50 Billion by 2027 - Cell Therapy Segment to Account for Half the Market...

Posted in Regenerative Medicine | Comments Off

Local Regenerative Medicine Clinic Ranks No. 62 on the 2021 Inc. 5000 – Franchising.com

Posted: August 18, 2021 at 2:09 am

By: QC Kinetix | 0Shares 26Reads

August 17, 2021 // Franchising.com // CHARLOTTE, N.C. - Inc. magazine today revealed that QC Kinetix is No. 62 on its annual Inc. 5000 list. The list represents a unique look at the most successful companies within the American economys most dynamic segmentits independent small businesses. The Charlotte, North Carolina-based company with a local presence, joins other well-known names like Intuit, Zappos, Under Armour, Microsoft, Patagonia, and many others who gained their first national exposure as honorees on the Inc. 5000.

We are honored and thrilled with our debut on the Inc. 5000 and especially with such a high ranking, said Justin Crowell, CEO of QC Kinetix. Our amazing growth really validates the science behind regenerative medicine and the work we are doing to bring our patients pain relief without surgery, pain pills, or downtime, so they can get back to living and doing the activities they enjoy pain-free.

Regenerative medicine develops treatment methods to regrow, repair, or replace damaged or diseased cells, organs, or tissues. This medical specialty uses the latest scientific research in the study of cells and tissue engineering to understand how the body can repair itself. For patients seeking relief from pain due to musculoskeletal injury, chronic joint pain, or hip, knee, or shoulder pain, regenerative procedures are the next frontier for treatment.

QC Kinetix differentiates itself by providing a high level of care and service to patients in a concierge setting that is unencumbered by insurance hassles. It is also the only regenerative medicine company offering a franchise opportunity to business owners who want to be part of this burgeoning medical specialty.

Chief Operating Officer and franchise industry veteran Scott Hoots credits the companys meteoric rise to a business model that combines purpose and profitability.

QC Kinetix is a brand with a purpose, which is to utilize the latest regenerative medicine treatments to enhance the quality of life for as many people as possible without the use of drugs or surgery. People are very motivated to use our cutting-edge treatments to help treat their pain and get back to living, and I think potential franchisees are highly interested in a franchise opportunity with a purpose-driven mission like ours, explained Hoots. There are many business opportunities out there today, but none that deliver a strong mix of financial performance plus a purpose-driven mission that has such a positive impact on peoples lives.

Not only have the companies on the 2021 Inc. 5000 been very competitive within their markets, but this years list also proved especially resilient and flexible given 2020s unprecedented challenges. Among the 5,000, the average median three-year growth rate soared to 543 percent, and median revenue reached $11.1 million. Together, those companies added more than 610,000 jobs over the past three years.

The 2021 Inc. 5000 list feels like one of the most important rosters of companies ever compiled, says Scott Omelianuk, editor-in-chief of Inc. Building one of the fastest-growing companies in America in any year is a remarkable achievement. Building one in the crisis weve lived through is just plain amazing. This kind of accomplishment comes with hard work, smart pivots, great leadership, and the help of a whole lot of people.

SOURCE QC Kinetix

###

Posted in Regenerative Medicine | Comments Off

Dr. Edward Nash Named Best Pain Management and Best Regenerative Medicine Doctor in The Woodlands by Living Magazine – Woodlands Online

Posted: August 18, 2021 at 2:09 am

THE WOODLANDS, TX -- 3R Regenerative Repair and Relief (3R) today announced Edward Nash, M.D, has been voted 2021 Best Pain Management Doctor and Best Regenerative Medicine Doctor in The Woodlands by Living Magazines 9th Annual Best Of Readers Choice Awards!

Dr. Nash, an MD and Physiatrist who specializes in pain management and regenerative medicine, is the owner of Progressive Pain and Rehabilitation and a partner at 3R Regenerative Repair and Relief in The Woodlands, just outside of Houston, Texas.

Dr. Nash was selected Best Pain Management Doctor and Best Regenerative Medicine Doctor in The Woodlands by Living Magazine readers who cast their votes in the annual Best Of competition in 150 categories that celebrate the best businesses, organizations, and people in dining, retail, entertainment, healthcare and home & garden in Houston Metro Area communities.

Its really an honor to be selected by the community and Living Magazine as a Best Of Award winner in two categories, said Dr. Nash. Im proud to be recognized among some of the best doctors and healthcare facilities in the Houston Area and passionate about raising the bar for safe, innovative pain management and healthcare solutions in our community.

Dr. Nash is a Houston native and a Diplomate of the American Board of Physical Medicine and Rehabilitation. He has been practicing medicine since earning his doctorate degree from the University of Texas-Houston in 2002. After completion of an internship in Internal Medicine from the University of Texas-Houston, he received specialty training from the prestigious allied Baylor College of Medicine and University of Texas-Houston Physical Medicine and Rehabilitation Department.

Following residency training, Dr. Nash joined KSF Orthopedic Center, where he became a partner and worked for 12 years. In 2018, he started Progressive Pain and Rehabilitation in The Woodlands to provide non-surgical advanced pain management solutions and custom treatment for his patients.

That same year, Dr. Nash partnered with Doctor Jeffery Pruski, D.C., to form 3R Regenerative Repair and Relief in The Woodlands to provide a combination of non-invasive biologic therapies, physical therapy and chiropractic care to patients suffering from back and joint pain, arthritis, neuropathy and sports injuries.

Doctors Nash and Pruski were some of the first to successfully use regenerative medicine, each individually, since 2014. The pair have helped hundreds of professional athletes and patients of all ages suffering from chronic pain, neck and back injuries, arthritis and degenerative conditions live healthier, pain-free lives.

Dr. Nash is a member of the American Academy of PMR, Texas Medical Association, Harris County Medical Society, American Academy of Regenerative Medicine, American Academy of Pain Medicine and the American Society of Interventional Pain. He has earned a number of prestigious awards over the course of his career including Texas Super Doctors (2015, 2016, 2017, 2018, 2019, 2020, 2021), Texas Rising Stars (2012, 2013, 2014), Compassionate Doctor Recognition (2010, 2011, 2015, 2016), Top 10 Doctor Houston 2014, Castle Connollys Top Doctors 2013, Patients Choice Award 2010, Doctors Choice 2011 and Living Magazines Best Regenerative Medicine Doctor in The Woodlands Readers Choice in 2020.

Visit link:
Dr. Edward Nash Named Best Pain Management and Best Regenerative Medicine Doctor in The Woodlands by Living Magazine - Woodlands Online

Posted in Regenerative Medicine | Comments Off

Regenerative Medicine Market to witness Robust Expansion by 2027 | ABS Protection GmbH, Mammut, Clarus Corporation – The Market Writeuo – The Market…

Posted: August 18, 2021 at 2:09 am

The updated report on theRegenerative Medicine marketgives a precise analysis of the value chain assessment for the review period of 2021 to 2027. The research includes an exhaustive evaluation of the administration of the key market companies and their revenue-generating business strategies adopted by them to drive sustainable business. TheService industryreport further enlists the market shortcomings, stability, growth drivers, restraining factors, opportunities for the projected timeframe.

Get Sample Report with Latest Industry Trends Analysis:

https://www.a2zmarketresearch.com/sample?reportId=538944

The top companies in this report include:

ABS Protection GmbH, Mammut, Clarus Corporation, Backcountry Access, Scott, Ortovox, ARVA, Osprey Packs, The North Face, Dakine, Mystery Ranch, Millet(Calida Group), Motorfist, Deuter.

The Global Regenerative Medicine market is expected to register a notable market expansion ofXX%during the review period owing to the largest market value in 2019. The market study provides a measure of the effectiveness of the product, real-time Regenerative Medicine market scenario, along custom ease. The study further offers market analysis, strategies and planning, R & D landscape, target audience management, market potential, due diligence, and competitive landscape.

Market Segmentation

Segment By Type

Mono Avalanche AirbagsDual Avalanche Airbags

Segment By Application

SkiingClimbingHiking

Scope of the report:

A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Regenerative Medicine market dynamics. The report includes Porters Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Regenerative Medicine research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics.

The Regenerative Medicine report highlights an all-inclusive assessment of the revenue generated by the various segments across different regions for the forecast period, 2021 to 2027. To leverage business owners, gain a thorough understanding of the current momentum, the Regenerative Medicine research taps hard to find data on aspects including but not limited to demand and supply, distribution channel, and technology upgrades. Principally, the determination of strict government policies and regulations and government initiatives building the growth of the Regenerative Medicine market offers knowledge of what is in store for the business owners in the upcoming years.

Request For Customized Report:

https://www.a2zmarketresearch.com/enquiry?reportId=538944

Geographic analysis

The global Regenerative Medicine market has been spread across North America, Europe, Asia-Pacific, the Middle East and Africa, and the rest of the world.

COVID-19 Impact Analysis

The pandemic of COVID-19 has emerged in lockdown across regions, line limitations, and breakdown of transportation organizations. Furthermore, the financial vulnerability Regenerative Medicine Market is a lot higher than past flare-ups like the extreme intense respiratory condition (SARS), avian influenza, pig influenza, bird influenza, and Ebola, inferable from the rising number of contaminated individuals and the vulnerability about the finish of the crisis. With the rapid rising cases, the worldwide Regenerative Medicine refreshments market is getting influenced from multiple points of view.

The accessibility of the labor force is by all accounts disturbing the inventory network of the worldwide Regenerative Medicine drinks market as the lockdown and the spread of the infection are pushing individuals to remain inside. The presentation of the Regenerative Medicine makers and the transportation of the products are associated. If the assembling movement is stopped, transportation and, likewise, the store network additionally stops. The stacking and dumping of the items, i.e., crude materials and results (fixings), which require a ton of labor, is likewise vigorously affected because of the pandemic. From the assembling plant entryway to the stockroom or from the distribution center to the end clients, i.e., application ventures, the whole Regenerative Medicine inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

Buy Exclusive Report:

https://www.a2zmarketresearch.com/buy?reportId=538944

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

[emailprotected]

+1 775 237 4147

Diyhomeimprovement Market to Witness Stunning Growth Sears Holding, Home Depot, HORNBACH Baumarkt, Les Mousquetaires, Kingfisher

See the rest here:
Regenerative Medicine Market to witness Robust Expansion by 2027 | ABS Protection GmbH, Mammut, Clarus Corporation - The Market Writeuo - The Market...

Posted in Regenerative Medicine | Comments Off

U of T’s Medicine by Design helps unite international researchers working to map every human cell – News@UofT

Posted: August 18, 2021 at 2:09 am

TheHuman Genome Project,a large-scale international effort to determine the complete DNA sequence that defines the human body, took more than 12 years to complete and involved thousands of researchers.

Now,a similar effort is underway to map each of the trillions of cells in the human body.

The Human Cell Atlas(HCA) would be acomprehensive map of cells that has the potential to rapidly advance the understanding of human health and the diagnosis, monitoring and treatment of disease, according to Gary Bader,a computational biologist and professor at the University of Torontos Donnelly Centre for Cellular and Biomolecular Research and the department of molecular genetics in the Temerty Faculty of Medicine.

This project will likely be larger than the Human Genome Project, and it requires a massive international effort. No single individual or institute could do this on their own, he says. Its multi-disciplinary in nature, and pulls in people from genomics and technology development, basic biology, clinical research, computational biology and ethics.

We encourage participation from all countries and relevant scientific communities.

Bader, who is on the organizing committee for HCA, is helping to co-ordinatea scientific meeting of the HCA from Aug. 25 to 27. The meeting will focus on human development and pediatrics, mapping the body from conception to adolescence. Medicine by Design is a lead sponsor of the meeting, along with theChan Zuckerberg Initiativeand others.

Bader says the August meeting will bring together groups of people who are working on critical questions about cell types and states during human development.

Were aiming to deliver a highly interactive meeting that will provide plenty of opportunities for virtual face-to-face interaction in breakout discussion sessions, Bader says. A silver lining of having the meeting online instead of in-person, as was originally planned, is that there are no space restrictions. It can be open to anyone who wants to attend. Also, there are no travel costs for attendees, and we are able to offer registration free of charge.

Session topics will include: understanding cellular decision-making during development;lineage tracing; clonal evolution; tagging and its applications;and developmental origins of health outcomes over a lifespan. There will also be a session on regenerative medicine, led byGuoji GuoandJason Rock, focusing on how developmental and pediatric single cell atlas data can shed light on tissue aging and repair processes.

Regenerative medicine uses stem cells to replace diseased tissues and organs, creating therapies in which cells are the biological product. Regenerative medicine can also mean triggering stem cells that are already present in the human body to repair damaged tissues or to modulate immune responses. Increasingly, regenerative medicine researchers are using a stem-cell lens to identify critical interactions or defects that prepare the ground for disease, paving the way for new approaches to preventing disease before it starts.

There is strong evidence that well have to really understand development to live up to regenerative medicines key aims, Bader says. There are questions we dont know the answer tofor example, why do children heal better than adults? These answers are essential for researchers who are developing stem cell therapies or ways to encourage self-repair in the body.

The HCA group is mapping 14 organ systems, each organized into its own bio network. For instance, the gut, heart and kidney each have their own bio network, comprisingresearchers that focus on that specific system. Bader is part of the liver bio network.

Bader, along with the Temerty Faculty of Medicine Associate ProfessorSonya MacParlandand ProfessorIan McGilvray a scientist,and surgeon and senior scientist, respectively,at University Health Network (UHN) are part of a Medicine by Design collaborative research team that, in 2018,created the firstmap of human liver cells at the molecular level. They are currently part of the large, Medicine by Design-funded team projectstudying how to harness the livers power to regenerate.

The liver map represents the first time a human organ has been charted at the single-cell level. It illuminated the basic biology of the liver in ways that could eventually increase the success of transplant surgery and enable powerful regenerative medicine treatments for liver disease such as regenerating the liver with stem cells.

This is a tool that can be used by researchers who are developing cells in the lab. For instance, a U of T and UHN teamrecently published work that showed they can develop functional blood vessel cells found in the liver. This drew on our liver map work, which provided a benchmark for those researchers to compare their cells with adult human liver cells, says Bader. HCA continues to expand this work for example in pediatricsand it will become a fundamental resource for regenerative medicine researchers.

Medicine by Design is sponsoring the HCA meeting in August because its an opportunity to engage with the international effort on human cell mapping, which creates new scientific collaborations for the Medicine by Design community.

Moreover, the HCA informs new directions in regenerative medicine research, says Michael Sefton, executive director of Medicine by Design and aUniversity Professorin the department of chemical engineering and applied chemistry in the Faculty of Applied Science & Engineering and theInstitute of Biomedical Engineering.

This international event will connect fields and people that traditionally dont work together, says Sefton, whose lab is located at the Donnelly Centre for Cellular and Biomolecular Research. A massive collaborative undertaking is whats necessary to bring HCA to fruition, and Medicine by Design is proud to support this effort. We cant overstate how much the HCA project could advance and transform regenerative medicine.

Bader says in addition to the opportunities for scientific learning, the event could have other benefits for attendees.

One of the advantages to attending the HCA meeting is the opportunity to network and potentially find out about funding opportunities one might not be aware of otherwise. Its a great opportunity for researchers to connect beyond their local collaborations.

Funded by a $114-million grant from theCanada First Research Excellence Fund, Medicine by Design brings together more than 150 principal investigators at U of T and its partner hospitals to advance regenerative medicine discoveries.

Original post:
U of T's Medicine by Design helps unite international researchers working to map every human cell - News@UofT

Posted in Regenerative Medicine | Comments Off

Monthly Archives: August 2021

Diabetes startup brews up $11M after ‘serendipitous spill’ led to creation of new CGM tech – FierceBiotech

Life Sciences Company GBS Develops Technology to Take the Fear out of Diabetes and COVID Testing – Yahoo Finance

Welwitschia: genetics unveil the secrets of the immortal plant – EL PAS in English

Join us today for Extra Crunch Live, as we speak with 1910 Genetics Jen Nwankwo and Playground Globals Jory Bell – TechCrunch

Lifeline Hospital offers solution for genetic diseases with advanced tech – The New Indian Express

Global Regenerative Medicine Market Research Report 2021: Market to Surpass $50 Billion by 2027 – Cell Therapy Segment to Account for Half the Market…

Local Regenerative Medicine Clinic Ranks No. 62 on the 2021 Inc. 5000 – Franchising.com

Dr. Edward Nash Named Best Pain Management and Best Regenerative Medicine Doctor in The Woodlands by Living Magazine – Woodlands Online

Regenerative Medicine Market to witness Robust Expansion by 2027 | ABS Protection GmbH, Mammut, Clarus Corporation – The Market Writeuo – The Market…

U of T’s Medicine by Design helps unite international researchers working to map every human cell – News@UofT

Categories

Archives

Recommended Sites

Contact Us

Recent Posts